Study on the Safety and Effects of WEF-001 for Advanced KRAS-Mutant Solid Tumors

Sponsor: Auricula Biosciences Inc.

Sponsor score: 0

ClinicalTrials ID:NCT07148128

Provider View

This clinical trial is testing a new drug, WEF-001, to see if it is safe and effective for treating advanced solid tumors with a specific KRAS mutation. The study focuses on patients whose cancer has not responded to standard treatments.

Patient Parameters

Program Overview

The purpose of this study is to evaluate the safety, tolerability, and initial effectiveness of a new drug called WEF-001 in patients with advanced solid tumors that have a specific KRAS mutation. Researchers aim to understand how the drug behaves in the body and its potential to treat these types of cancers.

Eligibility Criteria

Inclusion Criteria

  • Have an advanced solid tumor with a KRAS mutation, such as pancreatic, colorectal, non-small cell lung, platinum-resistant ovarian, bile duct, or bladder cancer.
  • The cancer must have progressed after receiving at least one standard treatment.
  • Have measurable cancer that can be tracked using standard criteria.
  • Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

  • Have an active infection that requires treatment within 28 days before starting the study.
  • Have active heart disease.
  • Have another active cancer that requires treatment.
  • Have liver problems.
  • Have untreated brain cancer or unstable neurological issues.
  • Have inflammatory bowel disease.
  • Have untreated overactive thyroid.
  • Have had lupus in the past 5 years.

Locations

FACILITYZIPCITYSTATE
NEXT Oncology Dallas75230DallasTexas
Next Oncology, San Antonio78229San AntonioTexas

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.